DelveInsight’s “Acute Kidney Injury (AKI) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Acute Kidney Injury market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Acute Kidney Injury market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Acute Kidney Injury (AKI): An Overview
Acute Kidney Injury (AKI), also known as acute renal failure (ARF), is a condition characterized by azotemia that progresses over several hours or days, with or without oliguria. AKI is commonly defined as an abrupt decline in renal function, clinically manifesting as an acute reversible increase in nitrogen waste products measured by blood urea nitrogen (BUN) and serum creatinine levels over the course of hours to weeks. The disease leads to abrupt kidney function loss, leading to waste product retention, electrolyte disturbances, and volume status changes.
Many people with acute kidney injury may be asymptomatic (no noticeable symptoms), and others may have generalized non-specific (not specific to kidneys) symptoms, such as nausea, vomiting, weakness, dizziness, pain in the lower back, passing less urine than usual, unexplained loss of appetite, feeling sick or vomiting, feeling short of breath and swelling of the legs or other body parts.
Acute Kidney Injury (AKI) Market Key Facts
-
The total Acute Kidney Injury market size in the United States is expected to increase with a CAGR of 3.7% during the study period (2019–2032).
-
According to the estimates, the highest Acute Kidney Injury market size is from the United States in 2021 and is anticipated to grow at a CAGR of 3.7%.
-
Among the EU5 countries, Germany has the maximum revenue share in 2021, while Spain has the lowest market share.
-
The Acute Kidney Injury market size in Japan is USD 1,051 million in 2021.
-
The Acute Kidney Injury epidemiology segment also provides the AKI epidemiology data and findings across the United States, the EU-5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
-
The total Mortality-adjusted Incident Cases of AKI in the 7MM comprised 6,470,038 cases in 2021 and are projected to increase during the forecast period.
-
The total Mortality-adjusted Incident Cases of AKI in the United States is 2,210,647 in 2021.
-
The US contributed to the largest incident population of AKI, accounting for ~ 34% of the 7MM in 2021.
-
Among the EU-5 countries, Germany accounted for the highest number of AKI cases, followed by France, whereas Spain accounted for the lowest cases in 2021.
-
In Japan, the total mortality-adjusted Incident Cases of AKI was 1,272,824 in 2021 and is anticipated to rise during the forecast period.
Acute Kidney Injury (AKI) Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Acute Kidney Injury market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Acute Kidney Injury market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Acute Kidney Injury (AKI) Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
The Report Covers the Acute Kidney Injury Epidemiology, Segmented as –
-
Total Incident Population of Acute Kidney Injury in Hospitalized Patients in 7MM [2019–2032]
-
Mortality Adjusted Incident Population of Acute Kidney Injury in Hospitalized Patients in 7MM [2019–2032]
-
Stage-specific Incident Population of Acute Kidney Injury in 7MM [2019–2032]
-
Age-specific Incident Population of Acute Kidney Injury [2019–2032]
Acute Kidney Injury (AKI) Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Acute Kidney Injury market or expected to be launched during the study period. The analysis covers the Acute Kidney Injury market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Acute Kidney Injury pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Acute Kidney Injury Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/acute-kidney-injury-aki-market
Acute Kidney Injury (AKI) Therapeutics Analysis
Currently, there is no targeted pharmacotherapy approved for the treatment of Acute Kidney Injury. At present, the therapeutic market size of Acute Kidney Injury is mainly dominated by the use of Renal Replacement Therapy (RRT) and off-label drugs, which include various classes such as ACE inhibitors, Angiotensin II-Receptor Blockers (ARBs), Diuretics, and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).
Several major pharma and biotech companies are developing therapies for Acute Kidney Injury. Currently, GUARD THERAPEUTICS is leading the therapeutics market with its Acute Kidney Injury drug candidates in the most advanced stage of clinical development.
A robust therapeutics pipeline with a novel mechanism of action and increasing incidence are major market drivers of the Acute Kidney Injury market. Additionally, the AKI pipeline is also expected to change the current dynamics of the market, which presently comprises biologics and molecules with new mechanisms of action like OCE-205, RBT-1, reCAP, RBT-1, bRESCAP, EA230, XRx-101,and others.
The Leading Companies in the Acute Kidney Injury (AKI) Therapeutics Market Include:
Alloksys Life Sciences, AM-Pharma Holding, Ampio Pharmaceuticals Inc., Angion Biomedica, Arch Biopartners Inc., Atorvia, CalciMedica Inc., EBI Exponential Biotherapies, Exponential Biotherapies, Guard Therapeutics, ILIAS Biologics Inc., MediBeacon, Metro International Biotech, LLC, Mission Therapeutics, Ocelot Bio, Inc, Pharming Technologies B.V., Quark-Pharmaceuticals, Rénibus Therapeutics, Sentien Biotechnologies, Serpin Pharma, Sulfateq BV, Vifor Pharma, XORTX Therapeutics, and others.
Acute Kidney Injury (AKI) Emerging and Marketed Drugs Covered in the Report Include:
-
bRESCAP: Alloksys
-
EA-230: Exponential Biotherapies
-
OCE-205:Ocelot Bio
-
RBT-1: Rénibus Therapeutics
-
recAP: AM Pharma
-
RMC-035 (ROSgard): Guard Therapeutics
-
SB-101: Sentien Biotechnologies
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
https://www.delveinsight.com/sample-request/acute-kidney-injury-aki-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Acute Kidney Injury Competitive Intelligence Analysis
4. Acute Kidney Injury Market Overview at a Glance
5. Acute Kidney Injury Disease Background and Overview
6. Acute Kidney Injury Patient Journey
7. Acute Kidney Injury Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Acute Kidney Injury Treatment Algorithm, Current Treatment, and Medical Practices
9. Acute Kidney Injury Unmet Needs
10. Key Endpoints of Acute Kidney Injury Treatment
11. Acute Kidney Injury Marketed Products
12. Acute Kidney Injury Emerging Drugs and Latest Therapeutic Advances
13. Acute Kidney Injury Seven Major Market Analysis
14. Attribute Analysis
15. Acute Kidney Injury Market Outlook (In US, EU5, and Japan)
16. Acute Kidney Injury Access and Reimbursement Overview
17. KOL Views on the Acute Kidney Injury Market
18. Acute Kidney Injury Market Drivers
19. Acute Kidney Injury Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/acute-kidney-injury-aki-market
Take control of your pharmaceutical portfolio with DelveInsight’s comprehensive consulting services. Get in touch and discover how we can help you manage your pharmaceutical portfolio today @ Pharmaceutical Portfolio Management Strategies
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/